Zai Lab Limited (NASDAQ:ZLAB) CEO Sells $1,723,500.00 in Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $34.47, for a total value of $1,723,500.00. Following the transaction, the chief executive officer now owns 494,117 shares in the company, valued at approximately $17,032,212.99. The trade was a 9.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ying Du also recently made the following trade(s):

• On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $32.44, for a total value of $1,622,000.00.

Zai Lab Trading Up 5.6 %

Shares of NASDAQ ZLAB opened at $35.91 on Thursday. Zai Lab Limited has a twelve month low of $13.48 and a twelve month high of $36.60. The stock has a fifty day simple moving average of $27.92 and a 200-day simple moving average of $26.18. The stock has a market capitalization of $3.93 billion, a PE ratio of -12.96 and a beta of 1.02.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The firm had revenue of $109.07 million during the quarter, compared to analyst estimates of $110.15 million. On average, equities analysts predict that Zai Lab Limited will post -2.58 earnings per share for the current year.

Institutional Investors Weigh In On Zai Lab

Institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in Zai Lab during the 4th quarter worth $29,000. Public Employees Retirement System of Ohio grew its stake in Zai Lab by 20.8% during the 4th quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company’s stock worth $484,000 after purchasing an additional 3,179 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Zai Lab by 2.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock worth $1,496,000 after purchasing an additional 1,200 shares in the last quarter. Woodline Partners LP grew its stake in Zai Lab by 9.4% during the 4th quarter. Woodline Partners LP now owns 1,759,797 shares of the company’s stock worth $46,089,000 after purchasing an additional 151,835 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new position in Zai Lab during the 4th quarter worth $7,857,000. 41.65% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Bank of America restated a “neutral” rating and issued a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a research report on Monday. Cantor Fitzgerald upgraded Zai Lab to a “strong-buy” rating in a research report on Tuesday.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.